L3VLUP
← Every manager
Free · no sign-up · Q2 2026

Which funds own RARE

Ultragenyx Pharmaceutical In in the Q2 2026 filings. At least 1 of the 91 current managers on file reported a position, worth $42m between them. It is among the largest positions of fewer than a fifth of the current managers on file. Buying and selling roughly cancelled this quarter, which is what a name looks like when the argument is still live.

Managers holding
1
at least, of 91 current
Combined value
$42m
as reported
Opened
0
new this quarter
Added to
0
already held
Trimmed or sold out
2
1 sold out entirely

Only each manager’s largest 200 positions are listed here, so a smaller holder may be missing.

Managers reporting a position

Largest first. Weight is the share of that manager’s whole reported book, which is the number worth quoting: $400m is a rounding error in one book and a defining bet in another.

ManagerValueWeightSharesChange on the quarterAction
Voloridge Investment Management LLC
Quantitative · $23.5bn book
$42m0.2%1,241,556+$12m-185,278Trimmed

Sold out of this quarter

Valued at what the position was worth in the previous filing, because by this one it is gone.

Ownership through time

At least 7 of the 95 managers whose filings are on file listed RARE in Q2 2026, against 2 in Q1 2014. 2 managers more than in Q1 2026: 3 listed it again; 1 no longer listed it among the positions read, which can mean a holding below the listed range, a filing that reported no holdings, or a filing not yet made.

Each manager’s largest 500 positions a quarter are read, so a small holding in a very large book can be missing, and a manager is counted as leaving only where its own filing shows it.

Managers on file listing it
0816Q1 2014: 214Q2 2014: 2Q3 2014: 2Q4 2014: 2Q1 2015: 615Q2 2015: 7Q3 2015: 9Q4 2015: 9Q1 2016: 316Q2 2016: 4Q3 2016: 6Q4 2016: 5Q1 2017: 517Q2 2017: 3Q3 2017: 3Q4 2017: 5Q1 2018: 618Q2 2018: 6Q3 2018: 6Q4 2018: 6Q1 2019: 719Q2 2019: 7Q3 2019: 6Q4 2019: 6Q1 2020: 620Q2 2020: 5Q3 2020: 6Q4 2020: 8Q1 2021: 1021Q2 2021: 14Q3 2021: 9Q4 2021: 8Q1 2022: 822Q2 2022: 8Q3 2022: 6Q4 2022: 8Q1 2023: 923Q2 2023: 11Q3 2023: 8Q4 2023: 9Q1 2024: 1224Q2 2024: 13Q3 2024: 16Q4 2024: 11Q1 2025: 825Q2 2025: 7Q3 2025: 8Q4 2025: 5Q1 2026: 526Q2 2026: 7
  • Q1 2014: 2
  • Q2 2014: 2
  • Q3 2014: 2
  • Q4 2014: 2
  • Q1 2015: 6
  • Q2 2015: 7
  • Q3 2015: 9
  • Q4 2015: 9
  • Q1 2016: 3
  • Q2 2016: 4
  • Q3 2016: 6
  • Q4 2016: 5
  • Q1 2017: 5
  • Q2 2017: 3
  • Q3 2017: 3
  • Q4 2017: 5
  • Q1 2018: 6
  • Q2 2018: 6
  • Q3 2018: 6
  • Q4 2018: 6
  • Q1 2019: 7
  • Q2 2019: 7
  • Q3 2019: 6
  • Q4 2019: 6
  • Q1 2020: 6
  • Q2 2020: 5
  • Q3 2020: 6
  • Q4 2020: 8
  • Q1 2021: 10
  • Q2 2021: 14
  • Q3 2021: 9
  • Q4 2021: 8
  • Q1 2022: 8
  • Q2 2022: 8
  • Q3 2022: 6
  • Q4 2022: 8
  • Q1 2023: 9
  • Q2 2023: 11
  • Q3 2023: 8
  • Q4 2023: 9
  • Q1 2024: 12
  • Q2 2024: 13
  • Q3 2024: 16
  • Q4 2024: 11
  • Q1 2025: 8
  • Q2 2025: 7
  • Q3 2025: 8
  • Q4 2025: 5
  • Q1 2026: 5
  • Q2 2026: 7
Their combined reported value
$0$2bn$3bnQ1 2014: $108m14Q2 2014: $103mQ3 2014: $237mQ4 2014: $187mQ1 2015: $676m15Q2 2015: $1.2bnQ3 2015: $1.3bnQ4 2015: $1.7bnQ1 2016: $933m16Q2 2016: $461mQ3 2016: $1.1bnQ4 2016: $1.2bnQ1 2017: $1.1bn17Q2 2017: $661mQ3 2017: $505mQ4 2017: $532mQ1 2018: $655m18Q2 2018: $1.3bnQ3 2018: $1.3bnQ4 2018: $598mQ1 2019: $1.3bn19Q2 2019: $1.3bnQ3 2019: $767mQ4 2019: $685mQ1 2020: $791m20Q2 2020: $1.5bnQ3 2020: $1.6bnQ4 2020: $3.0bnQ1 2021: $2.6bn21Q2 2021: $2.3bnQ3 2021: $2.0bnQ4 2021: $1.6bnQ1 2022: $1.5bn22Q2 2022: $1.1bnQ3 2022: $487mQ4 2022: $604mQ1 2023: $502m23Q2 2023: $619mQ3 2023: $397mQ4 2023: $593mQ1 2024: $513m24Q2 2024: $413mQ3 2024: $809mQ4 2024: $243mQ1 2025: $158m25Q2 2025: $120mQ3 2025: $94mQ4 2025: $43mQ1 2026: $48m26Q2 2026: $396m
  • Q1 2014: $108m
  • Q2 2014: $103m
  • Q3 2014: $237m
  • Q4 2014: $187m
  • Q1 2015: $676m
  • Q2 2015: $1.2bn
  • Q3 2015: $1.3bn
  • Q4 2015: $1.7bn
  • Q1 2016: $933m
  • Q2 2016: $461m
  • Q3 2016: $1.1bn
  • Q4 2016: $1.2bn
  • Q1 2017: $1.1bn
  • Q2 2017: $661m
  • Q3 2017: $505m
  • Q4 2017: $532m
  • Q1 2018: $655m
  • Q2 2018: $1.3bn
  • Q3 2018: $1.3bn
  • Q4 2018: $598m
  • Q1 2019: $1.3bn
  • Q2 2019: $1.3bn
  • Q3 2019: $767m
  • Q4 2019: $685m
  • Q1 2020: $791m
  • Q2 2020: $1.5bn
  • Q3 2020: $1.6bn
  • Q4 2020: $3.0bn
  • Q1 2021: $2.6bn
  • Q2 2021: $2.3bn
  • Q3 2021: $2.0bn
  • Q4 2021: $1.6bn
  • Q1 2022: $1.5bn
  • Q2 2022: $1.1bn
  • Q3 2022: $487m
  • Q4 2022: $604m
  • Q1 2023: $502m
  • Q2 2023: $619m
  • Q3 2023: $397m
  • Q4 2023: $593m
  • Q1 2024: $513m
  • Q2 2024: $413m
  • Q3 2024: $809m
  • Q4 2024: $243m
  • Q1 2025: $158m
  • Q2 2025: $120m
  • Q3 2025: $94m
  • Q4 2025: $43m
  • Q1 2026: $48m
  • Q2 2026: $396m

Between the quarter ends of Q1 2026 and Q2 2026. Each change in shares is valued at the Q2 2026 price, so the price’s own move is left out; a 13F shows the two quarter ends, not when in between anything was bought or sold.

Started in Q2 2026

No manager on file started a position.

Largest increases, by shares

No manager on file bought more.

Largest decreases, by shares

Left it

No manager on file is shown leaving it.

ManagerValue over timeFirst listedLargestQ2 2026
AQR Capital Management LLCQ3 2024$214m$214m
Two Sigma Investments LPQ2 2015$121m$121m
Voloridge Investment Management LLCQ2 2018$41m$41m
Walleye Capital LLCQ2 2024$16m$11m
Moore Capital Management LPQ1 2015$14m$4.3m
Brevan Howard Capital Management LPQ3 2024$4.5m$3.4m
PDT Partners LLCQ2 2021$5.7m$514k
T. Rowe Price Associates IncQ4 2015$1.3bnlast listed Q3 2024
Capital Research Global InvestorsQ1 2014$1.0bnlast listed Q4 2021
Fidelity (FMR LLC)Q1 2015$653mlast listed Q1 2017
Wellington Management Group LLPQ2 2015$468mlast listed Q3 2024
Capital World InvestorsQ1 2014$433mlast listed Q2 2022
Citadel Advisors LLCQ1 2020$177mlast listed Q2 2021
AllianceBernstein LPQ3 2015$164mlast listed Q3 2024
D. E. Shaw & Co.Q4 2020$99mlast listed Q2 2021
Marshall Wace LLPQ1 2015$71mlast listed Q4 2024
Point72 Asset Management LPQ4 2018$67mlast listed Q1 2025

What RARE is worth

Knowing who owns it is half the question. The other half is what it is worth against the companies it trades beside, which is the one an interviewer will follow up with.

Build the comp set around RARE →

How much of the picture this is

A Form 13F reports US-listed long equity and nothing else: no shorts, no bonds, no cash and no non-US listings. It arrives forty-five days after the quarter ends, so a manager who sold in July still shows the position in a filing published in August. This page reads the managers on file here rather than every filer in the market, and each manager’s largest positions rather than the whole table, so a small position in a very large book may not appear. Say “their last filing showed” rather than “they own”, and the distinction will do you credit.

What to do with a name the funds are buying

Knowing who owns something is the start of a pitch, not the pitch. The next questions are what it is worth and why they were buying.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More

The holdings, every quarter, and the week between

One email a week on what moved in the market and what it means for the people interviewing into it, with the 13F changes the quarter they are filed.

One email a week, free, and you can leave at any point.